• 四川大學(xué)華西醫(yī)院放射科(成都 610041);

目的  探討磁共振雙功能對比劑釓貝酸二葡甲胺（Gd-BOPTA）在肝臟局灶性病變和膽道系統(tǒng)疾病診斷中的應(yīng)用價(jià)值。方法  在CNKI及PubMed上檢索近年來Gd-BOPTA在肝臟局灶性病變及膽道系統(tǒng)病變診斷中應(yīng)用的文獻(xiàn)，對其應(yīng)用價(jià)值進(jìn)行綜述。結(jié)果  在肝臟局灶性病變的診斷方面，Gd-BOPTA除了能反映病灶的血供情況外，還能反映病灶內(nèi)肝細(xì)胞的功能狀態(tài)。在膽道系統(tǒng)評價(jià)方面，Gd-BOPTA可以用于評價(jià)膽囊運(yùn)動(dòng)功能、膽管解剖結(jié)構(gòu)、變異及病變情況。結(jié)論  Gd-BOPTA對肝臟局灶性病變和膽道系統(tǒng)疾病的診斷有重要價(jià)值，具有廣闊的應(yīng)用前景。

引用本文： 鐘歡歡,宋彬,陳光文. Gd-BOPTA在肝臟局灶性病變及膽道系統(tǒng)疾病診斷中的應(yīng)用價(jià)值. 中國普外基礎(chǔ)與臨床雜志, 2009, 16(12): 1042-1046. doi: 復(fù)制

1. Gallez B, Bacic G, Swartz HM. Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP [Ｊ]. Magn Reson Med, 1996; 35(1): 14-19.
2. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase Ⅲ clinical study [Ｊ]. Radiology, 2000; 215(3): 727-736.
3. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions [Ｊ]. AJR Am J Roentgenol, 2000; 175(4): 1111-1120.
4. Helmberger T, Semelka RC. New contrast agents for imaging the liver [Ｊ]. Magn Reson Imaging Clin N Am, 2001; 9(4): 745-766.
5. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine [Ｊ]. Radiology, 2001; 221(3): 731-739.
6. del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations [Ｊ]. Radiology, 2002; 225(3): 766-772.
7. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview [Ｊ]. Invest Radiol, 1998; 33(11): 798-809.
8. Giovagnoni A, Paci E. Liver. Ⅲ: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg) [Ｊ]. Magn Reson Imaging Clin N Am, 1996; 4(1): 61-72.
9. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging [Ｊ]. Invest Radiol, 1993; 28(8): 753-761.
10. Shellock FG, Parker JR, Venetianer C, et al. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance [Ｊ]. Invest Radiol, 2006; 41(6): 500-509.
11. Jeng CM, Tai SC, Wang YC, et al. Assessment of the adverse reactions of gadobenate dimeglumine (Gd-BOPTA) from preliminary clinical experience in taiwan [Ｊ]. Chin J Radiol, 2005; 30: 257-262.
12. Davies BE, Kirchin MA, Bensel K, et al. Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function [Ｊ]. Invest Radiol, 2002; 37(5): 299-308.
13. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned [Ｊ]. AJR Am J Roentgenol, 2007; 188(2): 586-592.
14. Townsend RR, Cohen DL, Katholi R, et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency [Ｊ]. Am J Kidney Dis, 2000; 36(6): 1207-1212.
15. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors [Ｊ]. Invest Radiol, 2001; 36(11): 632-641.
16. 譚國強(qiáng), 龍晚生, 周偉, 等. 肝局灶性結(jié)節(jié)增生的CT診斷及病理對照 [Ｊ]. 放射學(xué)實(shí)踐， 2008; 23（9）: 1018-1020.
17. 李迎春, 宋彬, 蔣莉莉, 等. 新型MR造影劑釓貝葡胺診斷肝臟局灶性結(jié)節(jié)樣增生的價(jià)值(附5例報(bào)告) [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2007; 14（5）: 598-604.
18. Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study [Ｊ]. Radiology, 2005; 236(1): 166-177.
19. Hwang HS, Kim SH, Jeon TY, et al. Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy [Ｊ]. Korean J Radiol, 2009; 10(3): 294-302.
20. Kim YK, Lee JM, Kim CS, et al. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging [Ｊ]. Eur Radiol, 2005; 15(2): 220-228.
21. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma [Ｊ]. Adv Anat Pathol, 2007; 14(3): 217-223.
22. 盧延, 張雪哲主編. 腹部疾病影像鑒別診斷 [M]. 北京: 化學(xué)工業(yè)出版社， 2008： 100-101.
23. Mitchell TS, Ellen RB, Paul J, et al. Fibrolamellar hepatocellular carcinoma [Ｊ]. Radio Graphics, 2008; 28（2）: 609-613.
24. 陳光文, 陳壢桃, 宋彬. 肝硬變相關(guān)結(jié)節(jié)的MR評價(jià) [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2009; 16（7）: 582-586.
25. 劉敏, 凌堅(jiān), 麥遠(yuǎn)鋒, 等. 惡性肝腫瘤釓貝葡胺MR增強(qiáng)延遲掃描表現(xiàn) [Ｊ]. 影像診斷與介入放射學(xué), 2006; 15（2）: 67-69.
26. 張國福, 周榮康, 嚴(yán)福華, 等. Gd-BOPTA增強(qiáng)MRI對小肝癌的診斷價(jià)值 [Ｊ]. 臨床放射學(xué)雜志, 2004; 23（12）: 1052-1057.
27. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation [Ｊ]. Radiology, 1997; 205(3): 721-728.
28. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings [Ｊ]. Invest Radiol, 2000; 35(1): 25-34.
29. Fayad LM, Holland GA, Bergin D, et al. Functional magnetic resonance cholangiography (fMRC) of the gallbladder and biliary tree with contrast-enhanced magnetic resonance cholangiography [Ｊ]. J Magn Reson Imaging, 2003; 18(4): 449-460.
30. Fink-Bennett D. Hepatobiliary imaging [A]. In: Henkin RE Eds. Nuclear medicine [M]. 2nd ed. Philadelphia, PA: Mosby Elsevier, 2006: 968-987.
31. Dahlstrm N, Persson A, Albiin N, et al. Contrast-enhan-ced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects [Ｊ]. Acta Radiol, 2007; 48(4): 362-368.
32. Lim JS, Kim MJ, Myoung S, et al. MR cholangiography for evaluation of hilar branching anatomy in transplantation of the right hepatic lobe from a living donor [Ｊ]. AJR Am J Roentgenol, 2008; 191(2): 537-545.
33. 王宏, 穆學(xué)濤, 吳春楠, 等. 活體肝移植供體膽管造影-磁共振膽管水成像和莫迪司增強(qiáng)膽管造影對比 [Ｊ]. 生物醫(yī)學(xué)工程與臨床, 2008; 13（3）: 193-197.
34. Akpinar E, Turkbey B, Karcaaltincaba M, et al. Initial experience on utility of gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted MR cholangiography in diagnosis of acute cholecystitis [Ｊ]. J Magn Reson Imaging, 2009; 30(3): 578-585.
  1. 1. Gallez B, Bacic G, Swartz HM. Evidence for the dissociation of the hepatobiliary MRI contrast agent Mn-DPDP [Ｊ]. Magn Reson Med, 1996; 35(1): 14-19.
  2. 2. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase Ⅲ clinical study [Ｊ]. Radiology, 2000; 215(3): 727-736.
  3. 3. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions [Ｊ]. AJR Am J Roentgenol, 2000; 175(4): 1111-1120.
  4. 4. Helmberger T, Semelka RC. New contrast agents for imaging the liver [Ｊ]. Magn Reson Imaging Clin N Am, 2001; 9(4): 745-766.
  5. 5. Grazioli L, Morana G, Federle MP, et al. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine [Ｊ]. Radiology, 2001; 221(3): 731-739.
  6. 6. del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations [Ｊ]. Radiology, 2002; 225(3): 766-772.
  7. 7. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA). An overview [Ｊ]. Invest Radiol, 1998; 33(11): 798-809.
  8. 8. Giovagnoni A, Paci E. Liver. Ⅲ: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg) [Ｊ]. Magn Reson Imaging Clin N Am, 1996; 4(1): 61-72.
  9. 9. Schuhmann-Giampieri G. Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging [Ｊ]. Invest Radiol, 1993; 28(8): 753-761.
  10. 10. Shellock FG, Parker JR, Venetianer C, et al. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance [Ｊ]. Invest Radiol, 2006; 41(6): 500-509.
  11. 11. Jeng CM, Tai SC, Wang YC, et al. Assessment of the adverse reactions of gadobenate dimeglumine (Gd-BOPTA) from preliminary clinical experience in taiwan [Ｊ]. Chin J Radiol, 2005; 30: 257-262.
  12. 12. Davies BE, Kirchin MA, Bensel K, et al. Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function [Ｊ]. Invest Radiol, 2002; 37(5): 299-308.
  13. 13. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned [Ｊ]. AJR Am J Roentgenol, 2007; 188(2): 586-592.
  14. 14. Townsend RR, Cohen DL, Katholi R, et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency [Ｊ]. Am J Kidney Dis, 2000; 36(6): 1207-1212.
  15. 15. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumors [Ｊ]. Invest Radiol, 2001; 36(11): 632-641.
  16. 16. 譚國強(qiáng), 龍晚生, 周偉, 等. 肝局灶性結(jié)節(jié)增生的CT診斷及病理對照 [Ｊ]. 放射學(xué)實(shí)踐， 2008; 23（9）: 1018-1020.
  17. 17. 李迎春, 宋彬, 蔣莉莉, 等. 新型MR造影劑釓貝葡胺診斷肝臟局灶性結(jié)節(jié)樣增生的價(jià)值(附5例報(bào)告) [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2007; 14（5）: 598-604.
  18. 18. Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study [Ｊ]. Radiology, 2005; 236(1): 166-177.
  19. 19. Hwang HS, Kim SH, Jeon TY, et al. Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy [Ｊ]. Korean J Radiol, 2009; 10(3): 294-302.
  20. 20. Kim YK, Lee JM, Kim CS, et al. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging [Ｊ]. Eur Radiol, 2005; 15(2): 220-228.
  21. 21. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma [Ｊ]. Adv Anat Pathol, 2007; 14(3): 217-223.
  22. 22. 盧延, 張雪哲主編. 腹部疾病影像鑒別診斷 [M]. 北京: 化學(xué)工業(yè)出版社， 2008： 100-101.
  23. 23. Mitchell TS, Ellen RB, Paul J, et al. Fibrolamellar hepatocellular carcinoma [Ｊ]. Radio Graphics, 2008; 28（2）: 609-613.
  24. 24. 陳光文, 陳壢桃, 宋彬. 肝硬變相關(guān)結(jié)節(jié)的MR評價(jià) [Ｊ]. 中國普外基礎(chǔ)與臨床雜志, 2009; 16（7）: 582-586.
  25. 25. 劉敏, 凌堅(jiān), 麥遠(yuǎn)鋒, 等. 惡性肝腫瘤釓貝葡胺MR增強(qiáng)延遲掃描表現(xiàn) [Ｊ]. 影像診斷與介入放射學(xué), 2006; 15（2）: 67-69.
  26. 26. 張國福, 周榮康, 嚴(yán)福華, 等. Gd-BOPTA增強(qiáng)MRI對小肝癌的診斷價(jià)值 [Ｊ]. 臨床放射學(xué)雜志, 2004; 23（12）: 1052-1057.
  27. 27. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation [Ｊ]. Radiology, 1997; 205(3): 721-728.
  28. 28. Grazioli L, Morana G, Caudana R, et al. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings [Ｊ]. Invest Radiol, 2000; 35(1): 25-34.
  29. 29. Fayad LM, Holland GA, Bergin D, et al. Functional magnetic resonance cholangiography (fMRC) of the gallbladder and biliary tree with contrast-enhanced magnetic resonance cholangiography [Ｊ]. J Magn Reson Imaging, 2003; 18(4): 449-460.
  30. 30. Fink-Bennett D. Hepatobiliary imaging [A]. In: Henkin RE Eds. Nuclear medicine [M]. 2nd ed. Philadelphia, PA: Mosby Elsevier, 2006: 968-987.
  31. 31. Dahlstrm N, Persson A, Albiin N, et al. Contrast-enhan-ced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects [Ｊ]. Acta Radiol, 2007; 48(4): 362-368.
  32. 32. Lim JS, Kim MJ, Myoung S, et al. MR cholangiography for evaluation of hilar branching anatomy in transplantation of the right hepatic lobe from a living donor [Ｊ]. AJR Am J Roentgenol, 2008; 191(2): 537-545.
  33. 33. 王宏, 穆學(xué)濤, 吳春楠, 等. 活體肝移植供體膽管造影-磁共振膽管水成像和莫迪司增強(qiáng)膽管造影對比 [Ｊ]. 生物醫(yī)學(xué)工程與臨床, 2008; 13（3）: 193-197.
  34. 34. Akpinar E, Turkbey B, Karcaaltincaba M, et al. Initial experience on utility of gadobenate dimeglumine (Gd-BOPTA) enhanced T1-weighted MR cholangiography in diagnosis of acute cholecystitis [Ｊ]. J Magn Reson Imaging, 2009; 30(3): 578-585.